Climb Bio (CLYM) news

Climb Bio added to Raymond James analyst favorites list

Climb Bio, Inc.: Oppenheimer raises target price to $25 from $18

Climb Bio, Inc. (CLYM) has seen recent analyst activity with Oppenheimer raising its price target for the stock to $25 from $18, reflecting a positive outlook on the clinical-stage biotechnology company’s prospects. The updated target aligns with broader analyst sentiment, as multiple firms have…

Climb Bio, Inc.: H.C. Wainwright raises target price to $30 from $24

H.C. Wainwright & Co. has revised its price target for Climb Bio, Inc. (NASDAQ: CLMB), raising it to $30 from $24 , reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and ongoing clinical trials, which have drawn…

Climb Bio Inc shares jump 14% after phase 1 data update

Climb Bio's CLYM116 shows ~29-day half-life in phase 1

Climb Bio, Inc. (Nasdaq: CLYM) recently reported preliminary data from its Phase 1 clinical trial of CLYM116, a preclinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand). The trial, conducted in normal healthy volunteers, demonstrated a half-life of approximately 29…